|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/25/20 Arcadia Biosciences, Inc. 10-K 12/31/19 93:12M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.06M
2: EX-4.7 Instrument Defining the Rights of Security Holders HTML 44K
3: EX-10.8 Material Contract HTML 97K
4: EX-23.1 Consent of Experts or Counsel HTML 28K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 36K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 36K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 30K
28: R1 Document and Entity Information HTML 94K
58: R2 Consolidated Balance Sheets HTML 128K
85: R3 Consolidated Balance Sheets (Parenthetical) HTML 37K
39: R4 Consolidated Statements of Operations and HTML 105K
Comprehensive Loss
27: R5 Consolidated Statements of Stockholders' Equity HTML 127K
57: R6 Consolidated Statements of Cash Flows HTML 176K
84: R7 Description of Business HTML 39K
38: R8 Summary of Significant Accounting Policies HTML 115K
29: R9 Recent Accounting Pronouncements HTML 36K
80: R10 Property and Equipment, Net HTML 66K
70: R11 Investments and Fair Value Measurements HTML 492K
22: R12 Consolidated Joint Venture HTML 32K
54: R13 Variable Interest Entity HTML 33K
81: R14 Accounts Payable and Accrued Expenses HTML 71K
71: R15 Collaborative Arrangements HTML 32K
23: R16 Notes Payable HTML 47K
55: R17 Private Placement and Registered Direct Offerings HTML 69K
79: R18 Stock-Based Compensation and Warrants HTML 147K
72: R19 Commitment and Contingencies HTML 60K
24: R20 Leases HTML 92K
36: R21 Income Taxes HTML 194K
86: R22 Retirement Benefits HTML 31K
59: R23 Segment Reporting HTML 52K
25: R24 Net Loss per Share HTML 45K
37: R25 Related Party Transactions HTML 31K
88: R26 Subsequent Events HTML 30K
60: R27 Summary of Significant Accounting Policies HTML 196K
(Policies)
26: R28 Summary of Significant Accounting Policies HTML 81K
(Tables)
35: R29 Property and Equipment, Net (Tables) HTML 63K
52: R30 Investments and Fair Value Measurements (Tables) HTML 497K
21: R31 Accounts Payable and Accrued Expenses (Tables) HTML 70K
74: R32 Notes Payable (Tables) HTML 50K
83: R33 Stock-Based Compensation and Warrants (Tables) HTML 120K
51: R34 Commitment and Contingencies (Tables) HTML 44K
20: R35 Leases (Tables) HTML 88K
73: R36 Income Taxes (Tables) HTML 194K
82: R37 Segment Reporting (Tables) HTML 53K
53: R38 Net Loss per Share (Tables) HTML 44K
19: R39 Description of Business - Additional Information HTML 61K
(Detail)
44: R40 Summary of Significant Accounting Policies - HTML 73K
Additional Information (Detail)
34: R41 Summary of Significant Accounting Policies - HTML 34K
Summary of Inventories, Net (Detail)
62: R42 Summary of Significant Accounting Policies - HTML 45K
Summary of Average Estimated Useful Lives of
Assets (Detail)
90: R43 Summary of Significant Accounting Policies - HTML 36K
Amounts Recognized in Consolidated Statements of
Operations and Comprehensive Loss Net (Detail)
43: R44 Property and Equipment, Net - Summary of Property HTML 50K
and Equipment, Net (Detail)
33: R45 Property and Equipment, Net - Additional HTML 35K
Information (Detail)
61: R46 Investments and Fair Value Measurements - Summary HTML 59K
of Amortized Cost and Fair Value of the
Available-For-Sale Investment Securities Portfolio
(Detail)
89: R47 Investments and Fair Value Measurements - HTML 30K
Additional Information (Detail)
45: R48 Investments and Fair Value of Financial HTML 68K
Instruments - Summary of Fair Value of Financial
Assets (Detail)
32: R49 Investments and Fair Value of Financial HTML 64K
Instruments - Summary of Warrant Liabilities
Measured and Recorded on Recurring Basis using
Black-Scholes Model (Detail)
16: R50 Investments and Fair Value of Financial HTML 71K
Instruments - Summary of Changes in Fair Value of
Liabilities (Detail)
49: R51 Consolidated Joint Venture - Additional HTML 44K
Information (Detail)
75: R52 Variable Interest Entity - Additional Information HTML 43K
(Detail)
66: R53 Accounts Payable and Accrued Expenses - Summary of HTML 54K
Accounts Payable and Accrued Expenses (Details)
17: R54 Collaborative Arrangements - Additional HTML 30K
Information (Detail)
50: R55 Notes Payable - Additional Information (Detail) HTML 36K
76: R56 Notes Payable - Summary of Maturities of Notes HTML 52K
Payable (Detail)
67: R57 Private Placement and Registered Direct Offerings HTML 348K
- Additional Information (Detail)
18: R58 Stock-Based Compensation and Warrants - Additional HTML 235K
Information (Detail)
48: R59 Stock-Based Compensation and Warrants - Summary of HTML 73K
Activity Under Stock Incentive Plans (Detail)
92: R60 Stock-Based Compensation and Warrants - HTML 37K
Weighted-Average Fair Value Assumption of Stock
Option Awards (Detail)
63: R61 Commitments and Contingencies - Additional HTML 64K
Information (Detail)
30: R62 Commitments and Contingencies - Schedule of HTML 32K
Minimum Funding Requirements Under Non-Cancelable
Agreement (Detail)
40: R63 Leases - Additional Information (Detail) HTML 47K
93: R64 Leases - Schedule of Leases (Detail) HTML 60K
64: R65 Leases - Schedule of Maturities of Operating Lease HTML 42K
Liabilities (Detail)
31: R66 Income Taxes - Components of Loss Before Income HTML 36K
Taxes (Detail)
41: R67 Income Taxes - Additional Information (Detail) HTML 57K
91: R68 Income Taxes - Schedule of Income Tax Expense HTML 58K
Comprised of Current State Taxes and Foreign Taxes
(Detail)
65: R69 Income Taxes - Reconciliation of Statutory Federal HTML 51K
Income Tax Rate to the Company's Effective Tax
Rate (Detail)
69: R70 Income Taxes - Summary of Company's Deferred Tax HTML 70K
Assets (Detail)
78: R71 Retirement Benefits - Additional Information HTML 37K
(Detail)
47: R72 Segment and Geographic Information - Additional HTML 29K
Information (Detail)
15: R73 Segment and Geographic Information - Summary of HTML 39K
Revenues Based on Location of Customers (Details)
68: R74 Net Loss per Share - Summary of Securities Not HTML 35K
Included in Diluted Per Share Calculations
(Detail)
77: R75 Related Party Transactions - Additional HTML 33K
Information (Detail)
46: R76 Subsequent Events - Additional Information HTML 37K
(Detail)
87: XML IDEA XML File -- Filing Summary XML 169K
56: EXCEL IDEA Workbook of Financial Reports XLSX 109K
9: EX-101.INS XBRL Instance -- rkda-20191231 XML 3.66M
11: EX-101.CAL XBRL Calculations -- rkda-20191231_cal XML 252K
12: EX-101.DEF XBRL Definitions -- rkda-20191231_def XML 870K
13: EX-101.LAB XBRL Labels -- rkda-20191231_lab XML 1.77M
14: EX-101.PRE XBRL Presentations -- rkda-20191231_pre XML 1.29M
10: EX-101.SCH XBRL Schema -- rkda-20191231 XSD 253K
42: ZIP XBRL Zipped Folder -- 0001564590-20-012875-xbrl Zip 231K
EXHIBIT 4.7
DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
As of the date of this Annual Report on Form 10-K, Arcadia Biosciences, Inc. (“Arcadia,” “we,” “us,” “our”) has one class of its securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock. The following summary of the terms of our capital stock is based upon our certificate of incorporation, as amended (“Certificate of Incorporation”) and our Amended and Restated Bylaws (“Bylaws”) and does not purport to be complete. This summary is subject to, and is qualified in its entirety by, or Certificate of Incorporation and Bylaws, each of which is incorporated by reference as exhibits to the Annual Report on Form 10-K of which this Exhibit is a part, and the applicable provisions of the Delaware General Corporation Law (“DGCL”). We encourage you to read our Certificate of Incorporation and Bylaws for additional information.
General
Our authorized capital stock consists of 150,000,000 shares of common stock, $0.001 par value, and 20,000,000 shares of preferred stock, $0.001 par value, all of which shares of preferred stock are undesignated.
Common Stock
Holders of our common stock are entitled to one vote per share for each share held of record on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Our Certificate of Incorporation does not provide for cumulative voting. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of legally available funds. Upon liquidation, dissolution or winding-up, the holders of our common stock are entitled to share ratably in all of our assets which are legally available for distribution, after payment of or provision for all liabilities and the liquidation preference of any outstanding preferred stock. The holders of our common stock have no preemptive, subscription, redemption or conversion rights.
Preferred Stock
The board of directors has the authority, without further action by the stockholders, to issue up to 20,000,000 shares of preferred stock, $0.001 par value per share, in one or more series. The board of directors will also have the authority to designate the rights, preferences, privileges and restrictions of each such series, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences, and the number of shares constituting any series.
The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of the company without further action by the stockholders. The issuance of preferred stock with voting and conversion rights may also adversely affect the voting power of the holders of common stock. In certain circumstances, an issuance of preferred stock could have the effect of decreasing the market price of the common stock.
Anti-Takeover Effects of Provisions of our Certificate of Incorporation and Bylaws
Our Certificate of Incorporation and Bylaws contain certain provisions that could have the effect of delaying, deterring or preventing another party from acquiring control of us. These provisions and certain provisions of the DGCL, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate more favorable terms with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us.
As discussed above, our board of directors will have the ability to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.
Limits on Ability of Stockholders to Act by Written Consent or Call a Special Meeting
Our Certificate of Incorporation provides that our stockholders may not act by written consent, which may lengthen the amount of time required to take stockholder actions. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with our Bylaws.
In addition, our Bylaws provide that special meetings of the stockholders may be called only by the majority of our board of directors. Stockholders may not call a special meeting, which may delay the ability of our stockholders to force consideration of a proposal or for holders controlling a majority of our capital stock to take any action, including the removal of directors.
Requirements for Advance Notification of Stockholder Nominations and Proposals
Our Bylaws require advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors. These provisions may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed. These provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company.
Board Classification
Our board of directors is divided into three classes, one class of which is elected each year by our stockholders. The directors in each class will serve three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board.
No Cumulative Voting
Our Certificate of Incorporation and Bylaws do not permit cumulative voting in the election of directors. Cumulative voting allows a stockholder to vote a portion or all of its shares for one or more candidates for seats on the board of directors. Without cumulative voting, a minority stockholder may not be able to gain as many seats on our board of directors as the stockholder would be able to gain if cumulative voting were permitted. The absence of cumulative voting makes it more difficult for a minority stockholder to gain a seat on our board of directors to influence our board’s decision regarding a takeover.
Amendment of Charter and Bylaws Provisions
The amendment of the above provisions of our Certificate of Incorporation requires approval by holders of at least two-thirds of our outstanding capital stock entitled to vote generally in the election of directors. The amendment of our Bylaws requires approval by the holders of at least two-thirds of our outstanding capital stock entitled to vote generally in the election of directors.
Delaware Anti-Takeover Statute
We are subject to the provisions of Section 203 of the DGCL, regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless:
|
|
• |
prior to the date of the transaction, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; |
|
|
• |
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, calculated as provided under Section 203; or |
|
|
• |
at or subsequent to the date of the transaction, the business combination is approved by our board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder. |
Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation’s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We anticipate that Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.
The provisions of the DGCL and the provisions of our Certificate of Incorporation and Bylaws, as amended upon the completion of this offering, could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions might also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem to be in their best interests.
Forum Selection
Our Certificate of Incorporation provides that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for:
|
|
• |
any derivative action or proceeding brought on our behalf; |
|
|
• |
any action asserting a breach of fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; |
|
|
• |
any action asserting a claim against us arising pursuant to any provisions of the DGCL, our Certificate of Incorporation or our Bylaws; or |
|
|
• |
any action asserting a claim against us that is governed by the internal affairs doctrine. |
These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Furthermore, the enforceability of similar choice of forum provisions in other companies’ charter documents has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find either exclusive-forum provision in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our business.
These exclusive-forum provisions are not intended to apply to any causes of action arising under the Securities Act of 1933 or the Exchange Act of 1934 or any other claim for which the federal courts have exclusive jurisdiction.
Listing
Our common stock is listed on the NASDAQ Capital Market under the symbol “RKDA”.
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/25/20 | 8-K | ||
| For Period end: | 12/31/19 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/29/24 Arcadia Biosciences, Inc. 10-K/A 12/31/23 10:1.4M Donnelley … Solutions/FA 3/28/24 Arcadia Biosciences, Inc. 10-K 12/31/23 102:14M Donnelley … Solutions/FA 4/13/23 Arcadia Biosciences, Inc. 10-K/A 12/31/22 12:2M Donnelley … Solutions/FA 3/30/23 Arcadia Biosciences, Inc. 10-K 12/31/22 110:18M Donnelley … Solutions/FA 9/27/22 Arcadia Biosciences, Inc. S-1 6:672K ActiveDisclosure/FA 3/31/22 Arcadia Biosciences, Inc. 10-K 12/31/21 114:19M Donnelley … Solutions/FA 1/28/22 Arcadia Biosciences, Inc. S-1 6:1.1M ActiveDisclosure/FA 3/31/21 Arcadia Biosciences, Inc. 10-K 12/31/20 103:14M ActiveDisclosure/FA 2/12/21 Arcadia Biosciences, Inc. 424B3 1:482K ActiveDisclosure/FA 2/02/21 Arcadia Biosciences, Inc. S-3 3:667K ActiveDisclosure/FA 9/11/20 Arcadia Biosciences, Inc. 424B3 1:190K ActiveDisclosure/FA 8/13/20 Arcadia Biosciences, Inc. S-3/A 3:383K ActiveDisclosure/FA |